With the improvement of living standards, the prevalence of diabetes is on the rise all over the world. It has become another non communicable chronic disease that seriously endangers human health. The prevention, diagnosis and treatment of diabetes and its complications are still the research focus of clinical medicine and biomedicine. As a dedicated CRO company, Ace Therapeutics offers a full range of research and therapy services related to diabetes.
Diabetes mellitus is a chronic, systemic, metabolic disease caused by the long-term combination of genetic factors and environmental factors, characterized by increased plasma glucose levels, mainly due to insufficient insulin secretion or dysfunction in the body (insulin resistance). The disorder of sugar, fat and protein metabolism caused can affect normal physiological activities and manifest as a variety of acute and chronic complications.
Glucose-Stimulated Insulin Secretion from Pancreatic β-Cells (Mourad, F.; et al. Trends in Cell Biology. 2016)
Diabetes is a chronic (long-lasting) health condition that affects how your body turns food into energy. When blood sugar goes up, it signals the pancreas to release insulin. The main types of diabetes include type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes (diabetes while pregnant) and other special types of diabetes (the diabetes caused by all causes except T1DM, T2DM and GDM).
All forms of diabetes increase the risk of long-term complications. The serious harm of diabetes is to cause many complications, including infectious diseases, atherosclerosis, microvascular disease, neurological complications and so on. The number of diabetes related deaths worldwide is about 1.5 million per year. It can be seen that diabetes is an area worthy of in-depth research, and more pathological research and therapy development are still needed.
Recombinant insulin and insulin analogs are the main drugs for clinical treatment of diabetes. In addition, there are new treatment methods such as islet/pancreas transplantation, but the technical methods are cumbersome and need to solve problems such as immune rejection.
| Monoclonal antibodies | Anti-inflammatory | Tolerance inducer | Insulin secretagogues | β-cell protective agent | Treg inducers |
| Anti-CD3 | Anti-IL-1 | GAD65 | GLP-1 analogs | Polyamine | IL-2 |
| Anti-CD20 | IL-1 antagonist | Insulin | DPP-IV inhibitor | EGF | IL-10 |
| ATG/ATS | HDAC inhibitor | HSP60 | Exenatide | GLP-1/ agonist | TGF-β |
| CTLA-4 | DNT | AAT | GM-CSF | ||
| CTLA4-Ig | Anti-TNF-α | GAD | |||
| PPI | Proinsulin |
Diabetes is an area worthy of further study, Ace Therapeutics provides diabetes-related services and products to accelerate your research. Mainly focus on preclinical services, including diabetes pathology research and new drug development.
As the preclinical research organization exclusively focused on diabetes, Ace Therapeutics has been involved in the development of relevant classes of therapy and glucose-lowering drugs, including drug development process of diabetes.
Diabetes is a field worthy of in-depth research. Ace Therapeutics provides research programs and technical services from pathological research to preclinical. providing our clients an advantage in a competitive landscape for novel and biosimilar medicines and therapy for diabetes.
Whether you are performing studies on new or modified medications, insulin alternatives or treatments about diabetes, Ace Therapeutics can support you the comprehensive products including mouse model, assay kits, antibodies, cell line, proteins and peptides, inhibitor and activator, etc.
Professional Team
Time-saving
One-stop Service
High Reputation
Ace Therapeutics guarantees to deliver our products and results on time. If you are interested in discussing how to get started with your study, please feel free to contact us.
